No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SGMO Sangamo Therapeutics
- 0.512
- +0.026+5.44%
Close Apr 19 16:00 ET
- 0.519
- +0.008+1.54%
Post 18:25 ET
104.18MMarket Cap-345P/E (TTM)
0.529High0.470Low1.05MVolume0.479Open0.485Pre Close534.03KTurnover0.56%Turnover RatioLossP/E (Static)203.67MShares1.78052wk High1.26P/B96.13MFloat Cap0.29152wk Low--Dividend TTM187.93MShs Float51.375Historical High--Div YieldTTM12.16%Amplitude0.291Historical Low0.508Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Global Clinical Trials Review 2024, Featuring Takeda Pharmaceutical, JCR Pharmaceuticals, GC Corp, RegenxBio, Sangamo Therapeutics and Generium
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today
Revenue Downgrade: Here's What Analysts Forecast For Sangamo Therapeutics, Inc. (NASDAQ:SGMO)
Today is shaping up negative for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly drac
12 Health Care Stocks Moving In Friday's Intraday Session
GainersIMAC Hldgs (NASDAQ:BACK) shares moved upwards by 91.5% to $2.47 during Friday's regular session. The market value of their outstanding shares is at $2.8 million. Virios Therapeutics (NASDAQ:VIR
Express News | Sangamo Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of a $24.0 Million Registered Direct Offering
Comments
The market anticipates continued poor revenue growth, potentially suppressing the P/S ratio. The company's forecast of declining revenue contributes to its low P/S. Without major changes, a drastic stock price increase seems unlikely.
2
$Sangamo Therapeutics(SGMO.US$ Sangamo Therapeutics Announces Data From STAC-BBB Demonstrating 'Robust Penetration of the Blood-brain Barrier (BBB) and Strong Transgene Expression Throughout the Central Nervous System (CNS) of NHPs'
Sangamo Therapeutics expected to release the good news on FDA approval.
$Sangamo Therapeutics(SGMO.US$ is likely to get FDA approval soon.
1
1
$Sangamo Therapeutics(SGMO.US$ 22 Feb 2024 positive results of IL23R - CAR will be announced at the ECCO 2024 meeting
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Stock_Drift : I have some $Sangamo Therapeutics (SGMO.US)$ shares.
TrytosaveabitOP Stock_Drift: Nice! You and me both!